Related Experiment Video
Updated: Aug 10, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Clinical experience with gefitinib: an update
Federico Cappuzzo1, Giovanna Finocchiaro, Giulio Metro
1Bellaria Hospital, Department of Medical Oncology, Bologna, Italy. federico.cappuzzo@ausl.bo.it
Abstract:
Gefitinib is an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that blocks signal transduction pathways involved in cell proliferation. This drug demonstrated impressive and durable responses in patients with heavily pretreated non-small cell lung cancer (NSCLC). In two large phase II trials, responses were observed in 9-19% of unselected patients, along with symptom improvement and benefit in quality of life. Biological mechanisms underlying TKI sensitivity have recently been discovered. There is evidence that specific EGFR gene mutations and/or amplification confer a particularly sensitive phenotype, especially in individuals with tumors demonstrating activation of the anti-apoptotic protein Akt. However, in all so far conducted clinical trials, no patient selection has been made, providing a logical explanation for the negative results observed in large phase III studies. In the present review, we will summarize the results observed in clinical trials with gefitinib. We will present results obtained in NSCLC and in other solid tumor, focusing on biological and clinical markers predicting drug sensitivity.
Insights
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows promise in non-small cell lung cancer (NSCLC). Patient selection based on EGFR mutations may improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gefitinib is a targeted therapy inhibiting epidermal growth factor receptor tyrosine kinase (EGFR-TKI).
- It has shown activity in non-small cell lung cancer (NSCLC), improving symptoms and quality of life.
- Previous trials with unselected patients yielded variable response rates (9-19%).
Purpose of the Study:
- To review clinical trial results of gefitinib in NSCLC and other solid tumors.
- To explore biological mechanisms of EGFR-TKI sensitivity.
- To identify predictive biomarkers for gefitinib efficacy.
Main Methods:
- Review of published clinical trials involving gefitinib.
- Analysis of biological data on EGFR mutations and signaling pathways.
- Correlation of clinical outcomes with molecular markers.
Main Results:
- Gefitinib demonstrated responses in heavily pretreated NSCLC patients.
- EGFR gene mutations and amplification are linked to increased sensitivity.
- Tumors with activated Akt signaling may also predict response.
- Lack of patient selection in prior phase III trials may explain negative results.
Conclusions:
- Gefitinib is an effective EGFR-TKI for NSCLC.
- Specific EGFR mutations and pathway activations are key predictors of gefitinib sensitivity.
- Future trials should incorporate patient selection based on these biomarkers for improved outcomes.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...